← TEVA PHARMACEUTICAL INDUSTRIES LTD

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $311.0m
($16.3b) -5329.90%
($2.1b) +86.78%
($999.0m) +53.53%
($4.0b) -299.40%
$417.0m +110.45%
($2.4b) -664.27%
($559.0m) +76.24%
($1.6b) -193.20%
$1.4b +186.03%
—
Net Income (Loss) Available to Common Stockholders, Basic $311.0m
($16.5b) -5413.50%
($2.4b) +85.48%
($999.0m) +58.36%
($4.0b) -299.40%
— ($2.4b)
($559.0m) +77.15%
($1.6b) -193.20%
$1.4b +186.03%
—
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest — ($16.4b) ($2.5b) ($1.0b) ($4.1b) $456.0m ($2.4b) ($615.0m) ($2.0b) $1.4b —
Net Income (Loss) Attributable to Noncontrolling Interest — ($184.0m) ($322.0m) ($2.0m) ($109.0m) $39.0m ($53.0m) ($56.0m) ($320.0m) $7.0m —
Depreciation and amortization — $2.1b $1.8b $1.7b $1.6b $1.3b $1.3b $1.2b $1.1b $1.0b $988.0m
Depreciation — $632.0m $676.0m $609.0m $537.0m $528.0m $576.0m $537.0m $471.0m $421.0m $424.0m
Amortization — $1.4b $1.2b $1.1b $1.0b $802.0m $732.0m $616.0m $588.0m $581.0m $573.0m
Depreciation Expense $1.5b — — — — — — — — — $988.0m
Depreciation Amortization Depletion — — — — — — $1.3b $1.2b $1.1b $1.0b $988.0m
Deferred Income Tax Expense (Benefit) — ($2.3b) ($895.0m) ($1.2b) ($350.0m) ($59.0m) ($1.1b) ($340.0m) ($418.0m) — ($485.0m)
Deferred Income Taxes Net And Uncertain Tax Positions $15.0m — — — — — — — — — ($485.0m)
Deferred Income Tax — — — — — — ($1.1b) ($317.0m) ($634.0m) ($671.0m) ($485.0m)
Deferred Tax — — — — — — ($1.1b) ($317.0m) ($634.0m) ($671.0m) ($485.0m)
Share-based Payment Arrangement, Noncash Expense — $133.0m $155.0m $119.0m $129.0m $119.0m $124.0m $121.0m $123.0m $157.0m $168.0m
Stock-Based Compensation Expense $124.0m — — — — — — — — — $168.0m
Equity Method Investment, Other than Temporary Impairment — — $0 — — — — — — — —
Goodwill, Impairment Loss — $17.1b $3.0b — $4.6b $0 $2.0b $700.0m $1.3b $0 $973.0m
Impairment of Intangible Assets (Excluding Goodwill) — $3.2b $2.0b $1.6b $1.5b $424.0m $355.0m $350.0m $251.0m $259.0m —
Impairment of Intangible Assets, Finite-lived — — — — — — — — — — —
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) — — — $1.8b — — — — — — —
Impairment of assets $1.6b — — — — — — — — — —
Other-than-temporary impairment $140.0m — — — — — — — — — —
Asset Impairment Charge — — — — — — $2.4b $1.1b $2.6b $1.0b $973.0m
Income (Loss) from Equity Method Investments — ($3.0m) ($71.0m) ($13.0m) $138.0m $9.0m $21.0m $2.0m $1.0m $15.0m —
Nonoperating Income (Expense) — ($895.0m) ($959.0m) ($822.0m) ($834.0m) ($1.1b) ($966.0m) ($1.1b) ($981.0m) ($934.0m) —
Changes in operating assets and liabilities:
Change In Working Capital — — — — — — $1.4b ($72.0m) ($435.0m) ($1.4b) ($1.1b)
Change In Receivables — — — — — — $334.0m $12.0m $245.0m ($173.0m) ($173.0m)
Changes In Account Receivables — — — — — — $334.0m $12.0m $245.0m ($173.0m) ($173.0m)
Increase (Decrease) in Inventories — $199.0m $26.0m $271.0m $41.0m $380.0m ($163.0m) ($147.0m) $166.0m $152.0m $152.0m
Inventory Write-down — — — — — — $4.2b — — — —
Inventories $372.0m — — — — — — — — — $152.0m
Inventory Step Up $381.0m — — — — — — — — — —
Change In Inventory — — — — — — ($163.0m) ($147.0m) $166.0m $152.0m $152.0m
Trade payable accrued expenses employee related obligations and other current liabilities $640.0m — — — — — — — — — —
Purchases of investments and other assets ($481.0m) — — — — — — — — — —
Change In Other Current Assets — — — — — — ($828.0m) ($1.5b) ($1.1b) ($1.3b) ($1.3b)
Other Operating Income (Expense), Net — — — $76.0m $40.0m $98.0m $107.0m $49.0m $14.0m ($18.0m) —
Net Cash Provided by (Used in) Operating Activities $5.2b
$2.2b -57.42%
$2.4b +9.93%
$748.0m -69.42%
$1.2b +62.57%
$798.0m -34.38%
$1.6b +99.25%
$1.4b -13.96%
$1.2b -8.85%
$1.6b +32.24%
$1.9b +15.04%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment ($901.0m) $874.0m $651.0m $525.0m $578.0m $562.0m $548.0m ($526.0m) ($498.0m) ($501.0m) ($551.0m)
Net (gain) loss from sale of long-lived assets and investments ($764.0m) — — — — — — — — — —
Proceeds from Investments $2.0b — — — — — — — — — $42.0m
Payments to Acquire Businesses, Net of Cash Acquired — ($43.0m) — — — — $7.0m $0 $15.0m $0 ($696.0m)
Acquisitions of businesses, net of cash acquired ($36.1b) — — — — — — — — — —
Payments for (Proceeds from) Other Investing Activities — $282.0m ($11.0m) ($58.0m) ($24.0m) ($1.0m) $0 $5.0m ($2.0m) ($5.0m) —
Other investing activities ($212.0m) — — — — — — — — — —
Net Other Investing Changes — — — — — $1.0m — ($5.0m) $2.0m $5.0m ($2.0m)
Net Cash Provided by (Used in) Investing Activities ($35.7b) $3.4b $1.9b $1.4b $863.0m $1.5b $656.0m $968.0m $792.0m $737.0m $38.0m
Cash flows from financing activities:
Repayments of Long-term Debt — $3.3b $7.4b $3.9b $1.9b $6.6b $1.4b $4.2b $1.6b $4.1b ($467.0m)
Issuance Of Debt — — — — — — $0 $3.2b $0 $2.3b ($7.0m)
Long Term Debt Issuance — — — — — — $0 $2.5b $0 $2.3b ($7.0m)
Long Term Debt Payments — — — — — — ($1.4b) ($4.2b) ($1.6b) ($4.1b) ($467.0m)
Net Issuance Payments Of Debt — — — — — — ($1.4b) ($1.7b) ($1.6b) ($1.8b) ($474.0m)
Net Long Term Debt Issuance — — — — — — ($1.4b) ($1.7b) ($1.6b) ($1.8b) ($474.0m)
Net Short Term Debt Issuance — — — — — — $0 $0 $0 $0 $0
Repayment Of Debt — — — — — — ($1.4b) ($4.9b) ($1.6b) ($4.1b) ($467.0m)
Short Term Debt Payments — — — — — — $0 ($700.0m) $0 $0 $0
Payments for Repurchase of Common Stock — — — — — — — — — — —
Payments of Ordinary Dividends, Common Stock — $901 $12 — — — — — — — —
Dividends paid on ordinary shares ($1k) — — — — — — — — — —
Dividends paid on preferred shares ($255) — — — — — — — — — —
Proceeds from (Payments for) Other Financing Activities — ($74.0m) ($57.0m) ($11.0m) ($5.0m) ($6.0m) ($118.0m) ($212.0m) ($8.0m) $41.0m —
Other financing activities ($169.0m) — — — — — — — — — —
Net Other Financing Charges — — — — — — ($118.0m) ($212.0m) ($150.0m) ($337.0m) $73.0m
Net Cash from Financing Activities $2.0b — — — — — — — — — —
Net Cash Provided by (Used in) Financing Activities $25.2b
($5.8b) -122.80%
($3.4b) +41.72%
($1.9b) +42.52%
($1.9b) +2.13%
($2.2b) -15.23%
($1.5b) +31.54%
($1.9b) -28.65%
($1.8b) +6.38%
($2.2b) -20.10%
($401.0m) +81.36%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — ($25.0m) $819.0m $193.0m $202.0m $21.0m $636.0m $393.0m $74.0m $256.0m $3.7b
Balance of cash and cash equivalents at beginning of period $988.0m — — — — — — — — — —
Beginning Cash Position — — — — — — $2.2b $2.8b $3.2b $3.3b $2.2b
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $963.0m $1.8b $2.0b $2.2b $2.2b $2.8b $3.2b $3.3b $3.6b $3.7b
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — $54.0m ($142.0m) $16.0m $8.0m ($128.0m) ($123.0m) ($30.0m) ($174.0m) $21.0m ($41.0m)
Effect of Exchange Rate on Cash ($660.0m) — — — — — — — — — ($41.0m)
Effect Of Exchange Rate Changes — — — — — — ($123.0m) ($30.0m) ($174.0m) $21.0m ($41.0m)
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised — — — — — — — — $19.0m $47.0m —
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities — $795.0m $815.0m $840.0m $846.0m $913.0m $948.0m $1.1b $1.0b $950.0m —
Income Taxes Paid, Net — $106.0m $420.0m $552.0m $709.0m $495.0m $543.0m $298.0m $471.0m — —
Additional Financial Items
Deconsolidation, Gain (Loss), Amount — ($396.0m) — — — — — — — — —
Foreign Currency Transaction Gain (Loss), before Tax — — — — — — — — — — —
Gain (Loss) on Disposition of Assets — — — — — $7.0m $18.0m $25.0m — — —
Gain (Loss) on Disposition of Business — $1.1b $67.0m $50.0m $8.0m $51.0m $46.0m $3.0m $15.0m ($22.0m) —
Gain (Loss) on Disposition of Assets for Financial Service Operations — $11.0m $9.0m ($1.0m) $11.0m — — — $2.0m $2.0m —
General and Administrative Expense — $1.5b $1.3b $1.2b $1.2b $1.1b $1.2b $1.2b $1.2b $1.3b —
Goodwill — $28.4b $24.9b $24.8b $20.6b $20.0b $17.6b $17.2b $15.1b $16.0b $973.0m
Income Tax Expense (Benefit) — ($1.9b) ($195.0m) ($278.0m) ($168.0m) $211.0m ($638.0m) ($7.0m) $676.0m ($180.0m) —
Net change in operating assets and liabilities $1.2b — — — — — — — — — —
Research and development in process $422.0m — — — — — — — — — —
Other items ($14.0m) — — — — — — — — — —
Stock Repurchases (Issuances) $329.0m — — — — — — — — — —
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs ADSs $329.0m — — — — — — — — — —
Purchase of treasury shares $0 — — — — — — — — — —
Proceeds from Stock Issuance $35.0m — — — — — — — — — —
Proceeds from long-term loans and other long-term liabilities, net of issuance costs $25.3b — — — — — — — — — —
Repayment of long-term loans And Other Long Term Liabilities ($999.0m) — — — — — — — — — —
Net change in cash and cash equivalents ($6.0b) — — — — — — — — — —
Interest Expense $290.0m — — — — — — — — — —
Income Tax Expense $341.0m — — — — — — — — — —
Shares Issuance To Allergan plc for the Actavis Generics acquisition $5.1b — — — — — — — — — —
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda $1.8b — — — — — — — — — —
Actavis Generics Contingent Consideration $302.0m — — — — — — — — — —
Trade Receivable $343.0m — — — — — — — — — —
Change in Other Working Capital ($517.0m) — — — — — — — — — —
Cash Flow From Continuing Financing Activities — — — — — — ($1.5b) ($1.9b) ($1.8b) ($2.2b) ($401.0m)
Cash Flow From Continuing Investing Activities — — — — — — $656.0m $968.0m $792.0m $737.0m $38.0m
Change In Account Payable — — — — — — $2.0b $1.6b $258.0m ($15.0m) ($15.0m)
Change In Cash Supplemental As Reported — — — — — — $636.0m $393.0m $74.0m $256.0m —
Change In Payable — — — — — — $2.0b $1.6b $258.0m ($15.0m) ($15.0m)
Changes In Cash — — — — — — $759.0m $423.0m $247.0m $235.0m $1.5b
End Cash Position — — — — — — $2.8b $3.2b $3.3b $3.6b $3.7b
Financing Cash Flow — — — — — — ($1.5b)
($1.9b) -28.65%
($1.8b) +6.38%
($2.2b) -20.10%
($401.0m) +81.36%
Free Cash Flow — — — — — — $1.0b $842.0m $749.0m $1.1b $1.3b
Gain Loss On Investment Securities — — — — — $104.0m $10.0m ($41.0m) — — —
Gain Loss On Sale Of Business — — — — — — $10.0m ($41.0m) ($22.0m) $0 ($20.0m)
Gain Loss On Sale Of PPE — — — — — $104.0m $10.0m — — — $10.0m
Interest Received CFI — — — — — — $1.1b $1.5b $1.3b $1.2b $1.2b
Investing Cash Flow — — — — — — $656.0m $968.0m $792.0m $737.0m $38.0m
Net Business Purchase And Sale — — — — — — $61.0m $68.0m $28.0m $34.0m ($642.0m)
Net Investment Purchase And Sale — — — — — — $3.0m ($46.0m) ($31.0m) ($15.0m) $11.0m
Net PPE Purchase And Sale — — — — — — ($548.0m) ($526.0m) ($498.0m) ($501.0m) ($551.0m)
Operating Gains Losses — — — — — $104.0m $10.0m ($41.0m) ($22.0m) — ($22.0m)
Other Non Cash Items — — — — — — ($91.0m) $61.0m $560.0m $81.0m —
Purchase Of Business — — — — — — ($7.0m) $0 ($15.0m) $0 ($696.0m)
Purchase Of Investment — — — — — — ($1.0m) ($46.0m) ($71.0m) ($57.0m) ($31.0m)
Purchase Of PPE — — — — — — ($548.0m) ($526.0m) ($498.0m) ($501.0m) ($551.0m)
Sale Of Business — — — — — — $68.0m $68.0m $43.0m $34.0m $54.0m
Sale Of Investment — — — — — — $4.0m $0 $40.0m $42.0m $42.0m
Stock Based Compensation — — — — — — $124.0m $121.0m $123.0m $157.0m $168.0m

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.